Advertisement Advanced BioScience Laboratories acquires majority stake in Platine - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Advanced BioScience Laboratories acquires majority stake in Platine

Advanced BioScience Laboratories (ABL), a US-based biomedical contract research and manufacturing organization, has acquired majority stake in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services.

Platine’s laboratories located in Lyon, France, will help clients in the biopharmaceutical, food, cosmetic and diagnostic industries to assess the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.

The company offers immunologic expertise and services using a broad range of in vitro platforms such as flow cytometry, ELISpot, ELISA, multiplex, Singulex, and MSD capabilities.

It also provides its Immuno’line T-cell activation service to evaluate the specific immune response to a particular therapeutic drug, vaccine, cosmetic, or food product of interest.

ABL president and CEO Thomas VanCott said: "We are extremely excited to have the Platine organization join ABL.

"Over the years, their staff of dedicated and highly talented scientists has proven their ability to deliver the highest quality of service, meeting clients’ immunological testing needs throughout the product development process.

"This acquisition also represents a significant step in the strategic growth of ABL, providing a European-based facility for clinical and other sample processing and immunomonitoring analyses.

"With laboratories based in France and the U.S., ABL is better positioned to support our clients’ increasingly global clinical development strategies."